



Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



CORRECTION

Author correction to “The upregulated intestinal folate transporters direct the uptake of ligand-modified nanoparticles for enhanced oral insulin delivery” [Acta Pharm Sin B 12 (2022) 1460–1472]



Jingyi Li^{a,b}, Yaqi Zhang^{b,c}, Miaorong Yu^b, Aohua Wang^{b,c}, Yu Qiu^{b,c},
Weiwei Fan^b, Lars Hovgaard^d, Mingshi Yang^e, Yiming Li^a,
Rui Wang^{a,*}, Xiuying Li^{f,*}, Yong Gan^{b,c,g,*}

^aSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

^bState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

^cUniversity of Chinese Academy of Sciences, Beijing 100049, China

^dOral Formulation Development, Novo Nordisk A/S, Maalov 2760, Denmark

^eDepartment of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark


^fUniversity of Texas at Dallas, Richardson, TX 75080, USA

^gNMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, National Institutes for Food and Drug Control, Beijing 100050, China

The authors regret an error in the presentation of Fig. 1B, where the GAPDH blot for the Duodenum panel of Diabetic GK rat group was inadvertently duplicated from the Ileum pane of STZ diabetic rat group. This correction does not affect the overall results or conclusions of the study. The authors would like to assure readers that the corrected image does not alter the validity of the research. The original data of these figures have been provided to the Editorial Office, and the corresponding author can be contacted for original data access.

The authors would like to apologize for any inconvenience caused.

The corrected Fig. 1B appears below:



DOI of original article: <https://doi.org/10.1016/j.apsb.2021.07.024>.

*Corresponding authors. Tel.: +86 021 51322181, fax: +86 021 51322193 (Rui Wang); Tel.: +01 972 883 4480, fax: +01 972 883 4440 (Xiuying Li); Tel.: +86 021 20231975, fax: +86 021 20231000 1425 (Yong Gan).

E-mail addresses: wr@shutcm.edu.cn (Rui Wang), Xiuying.Li@utdallas.edu (Xiuying Li), ygan@simm.ac.cn (Yong Gan).

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2025.04.015>

2211-3835 © 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. All rights are reserved, including those for text and data mining, AI training, and similar technologies.